Igc pharma's tgr-63 preclinical results show substantial reduction in amyloid plaque, a key hallmark of alzheimer's disease

Potomac, md.--(business wire)-- #ad--igc pharma's tgr-63 preclinical results show substantial reduction in amyloid plaque, a key hallmark of alzheimer's disease.

IGC Ratings Summary

IGC Quant Ranking